Highlight on lipids and its use for covalent and non-covalent conjugations

Abdullah Q. Khudhur; Nidhal K. Maraie; Ayad M.R. Raauf

doi:10.32947/ajps.v20i3.754

Authors

Abdullah Q. Khudhur Department of Pharmaceutics, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq
Nidhal K. Maraie Department of Pharmaceutics, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq
Ayad M.R. Raauf Department of Pharmaceutical Chemistry, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq

DOI:

https://doi.org/10.32947/ajps.v20i3.754

Keywords:

Assay, (HPLC) High performance liquid chromatography, (AUP) Area under the peak, Ampicillin Trihydrate (AMP. Tri. H).

Abstract

Lipids are organic fatty or waxy compounds which are used to make nanocarriers that are promising for drug delivery. When lipids associated covalently (lipid-drug conjugate LDC) or non- covalently (drug-lipid complex) to drugs to form Lipid Drug Conjugates (LDC). Most common types of lipids

used for drug conjugation are fatty acids, glycerides, steroids, and phospholipids. Conjugation with lipids may change the properties of the drug and significantly increase the drug lipophilicity. Lipid-drug conjugation could improve the delivery of drugs by the lymphatic system, enhance bioavailability of oral administered drugs, improve drug targeting in tumor diseases, enhance the loading of drugs into some delivery carriers, increase drug stability, and many others. Lipid-drug conjugates can be prepared through different strategies for conjugation and by chemical linkers depending on the chemical structure of both drugs and lipids, careful selection of lipids and drug are necessary in designing the lipid-drug conjugate to achieve maximum benefits.

References

Gurr MI, Harwood JL, Frayn KN, Murphy DJ, Michell RH. Lipids: biochemistry, biotechnology and health: John Wiley & Sons; 2016.

Kovačević AB. Lipid nanocarriers for delivery of poorly soluble and poorly permeable drugs. Nanopharmaceuticals: Elsevier; 2020. p. 151-74. DOI: https://doi.org/10.1016/B978-0-12-817778-5.00008-7

Lambert DM. Rationale and applications of lipids as prodrug carriers. European journal of pharmaceutical sciences. 2000;11: S15-S27. DOI: https://doi.org/10.1016/S0928-0987(00)00161-5

Hussain A, Usman Mohd Siddique M, Kumar Singh S, Samad A, Beg S, Wais M. Lipid-drug conjugates for oral bioavailability enhancement. Recent Patents on Nanomedicine. 2015; 5:87-95. DOI: https://doi.org/10.2174/1877912305666150616220747

Negi JS. Nanolipid Materials for Drug Delivery Systems: A Comprehensive Review. Characterization and Biology of Nanomaterials for Drug Delivery: Elsevier; 2019. p. 137-63. DOI: https://doi.org/10.1016/B978-0-12-814031-4.00006-4

Neupane YR, Sabir M, Ahmad N, Ali M, Kohli K. Lipid drug conjugate nanoparticle as a novel lipid nanocarrier for the oral delivery of decitabine: ex vivo gut permeation studies. Nanotechnology. 2013; 24:415102. DOI: https://doi.org/10.1088/0957-4484/24/41/415102

Irby D, Du C, Li F. Lipid–drug conjugate for enhancing drug delivery. Molecular pharmaceutics. 2017;14(5):1325-38. DOI: https://doi.org/10.1021/acs.molpharmaceut.6b01027

Zaro JL. Lipid-based drug carriers for prodrugs to enhance drug delivery. The AAPS journal. 2015; 17:83-92. DOI: https://doi.org/10.1208/s12248-014-9670-z

Markovic M, Ben-Shabat S, Keinan S, Aponick A, Zimmermann EM, Dahan A. Prospects and challenges of phospholipid-based prodrugs. Pharmaceutics. 2018;10(4):210. DOI: https://doi.org/10.3390/pharmaceutics10040210

SUGIHARA J, FURUUCHI S, ANDO H, TAKASHIMA K, HARIGAYA S. Studies on intestinal lymphatic absorption of drugs. II. Glyceride prodrugs for improving lymphatic absorption of naproxen and nicotinic acid. Journal of pharmacobio-dynamics. 1988;11(8):555-62. DOI: https://doi.org/10.1248/bpb1978.11.555

Berry SE. Triacylglycerol structure and interesterification of palmitic and stearic acid-rich fats: an overview and implications for cardiovascular disease. Nutrition research reviews. 2009; 22:3-17. DOI: https://doi.org/10.1017/S0954422409369267

Radwan AA, Alanazi FK. Targeting cancer using cholesterol conjugates. Saudi pharmaceutical journal. 2014; 22:3-16. DOI: https://doi.org/10.1016/j.jsps.2013.01.003

Wang H, Feng Z, Wu D, Fritzsching KJ, Rigney M, Zhou J, et al. Enzyme-regulated supramolecular assemblies of cholesterol conjugates against drug-resistant ovarian cancer cells. Journal of the American Chemical Society. 2016;138(34):10758-61. DOI: https://doi.org/10.1021/jacs.6b06075

Yadav K, Bhargava P, Bansal S, Singh M, Gupta S, Sandhu G, et al. Nature of the charged head group dictates the anticancer potential of lithocholic acid-tamoxifen conjugates for breast cancer therapy. MedChemComm. 2015; 6:778-87. DOI: https://doi.org/10.1039/C4MD00289J

Khan I, Elhissi A, Shah M, Alhnan MA, Ahmed W. Liposome-based carrier systems and devices used for pulmonary drug delivery. Biomaterials and Medical Tribology: Elsevier; 2013. p. 395-443. DOI: https://doi.org/10.1533/9780857092205.395

Fricker G, Kromp T, Wendel A, Blume A, Zirkel J, Rebmann H, et al. Phospholipids and lipid-based formulations in oral drug delivery. Pharmaceutical research. 2010; 27:1469-86. DOI: https://doi.org/10.1007/s11095-010-0130-x

Alexander RL, Greene BT, Torti SV, Kucera GL. A novel phospholipid gemcitabine conjugate is able to bypass three drug-resistance mechanisms. Cancer chemotherapy and pharmacology. 2005; 56:15-21. DOI: https://doi.org/10.1007/s00280-004-0949-0

Mukherjee S, Ray S, Thakur R. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian journal of pharmaceutical sciences. 2009; 71:349. DOI: https://doi.org/10.4103/0250-474X.57282

MacDonald GE, Lada RR, Caldwell CD, Udenigwe C, MacDonald MT. Potential Roles of Fatty Acids and Lipids in Postharvest Needle Abscission Physiology. American Journal of Plant Sciences. 2019; 10:1069-89. DOI: https://doi.org/10.4236/ajps.2019.106078

Babič A, Herceg V, Bastien E, Lassalle H-P, Bezdetnaya L, Lange N. 5-aminolevulinic acid-squalene nanoassemblies for tumor photodetection and therapy: In vitro studies. Nanoscale research letters. 2018;13(1):10. DOI: https://doi.org/10.1186/s11671-017-2408-y

Fumagalli G, Giorgi G, Vágvölgyi Mt, Colombo E, Christodoulou MS, Collico V, et al. Heteronanoparticles by Self-Assembly of Ecdysteroid and Doxorubicin Conjugates to Overcome Cancer Resistance. ACS medicinal chemistry letters. 2018;9(5):468-71. DOI: https://doi.org/10.1021/acsmedchemlett.8b00078

Qiu Q, Li C, Song Y, Shi T, Luo X, Zhang H, et al. Targeted delivery of ibrutinib to tumor-associated macrophages by sialic acid-stearic acid conjugate modified nanocomplexes for cancer immunotherapy. Acta biomaterialia. 2019; 92:184-95. DOI: https://doi.org/10.1016/j.actbio.2019.05.030

Ding Y, Nielsen KA, Nielsen BP, Bøje NW, Müller RH, Pyo SM. Lipid-drug-conjugate (LDC) solid lipid nanoparticles (SLN) for the delivery of nicotine to the oral cavity–optimization of nicotine loading efficiency. European Journal of Pharmaceutics and Biopharmaceutics. 2018; 128:10-7. DOI: https://doi.org/10.1016/j.ejpb.2018.03.004

Wong T, Narayanan S, Brown DP, Chen Z-S. Synthesis and Cytotoxicity Studies of Stilbene Long-Chain Fatty Acid Conjugates. Journal of Natural Products. 2020. DOI: https://doi.org/10.1021/acs.jnatprod.0c00027

Thanki K, Prajapati R, Sangamwar AT, Jain S. Long chain fatty acid conjugation remarkably decreases the aggregation induced toxicity of Amphotericin B. International journal of pharmaceutics. 2018;544(1):1-13. DOI: https://doi.org/10.1016/j.ijpharm.2018.04.009

Chrzanowska A, Roszkowski P, Bielenica A, Olejarz W, Stępień K, Struga M. Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates. European journal of medicinal chemistry. 2020; 185:111810. DOI: https://doi.org/10.1016/j.ejmech.2019.111810

Kubo T, Nishimura Y, Hatori Y, Akagi R, Mihara K, Yanagihara K, et al. Antitumor effect of palmitic acid‐conjugated Dsi RNA for colon cancer in a mouse subcutaneous tumor model. Chemical biology & drug design. 2019;93(4):570-81. DOI: https://doi.org/10.1111/cbdd.13454

Du Y, Ling L, Ismail M, He W, Xia Q, Zhou W, et al. Redox sensitive lipid-camptothecin conjugate encapsulated solid lipid nanoparticles for oral delivery. International journal of pharmaceutics. 2018;549(1-2):352-62. DOI: https://doi.org/10.1016/j.ijpharm.2018.08.010

Jiang S, Liu Z, Wu L, Yuan Y, Hu Y, Zhang X, et al. Tumor targeting with docosahexaenoic acid‑conjugated docetaxel for inhibiting lung cancer metastasis to bone. Oncology letters. 2018;16(3):2911-20. DOI: https://doi.org/10.3892/ol.2018.9047

Mielczarek-Puta M, Struga M, Roszkowski P. Synthesis and anticancer effects of conjugates of doxorubicin and unsaturated fatty acids (LNA and DHA). Medicinal Chemistry Research. 2019;28(12):2153-64. DOI: https://doi.org/10.1007/s00044-019-02443-0

Augimeri G, Plastina P, Gionfriddo G, Rovito D, Giordano C, Fazio A, et al. N-Eicosapentaenoyl Dopamine, A Conjugate of Dopamine and Eicosapentaenoic Acid (EPA), Exerts Anti-inflammatory Properties in Mouse and Human Macrophages. Nutrients. 2019;11(9):2247. DOI: https://doi.org/10.3390/nu11092247

Zahedifard F, Lee H, No JH, Salimi M, Seyed N, Asoodeh A, et al. Anti-leishmanial activity of Brevinin 2R and its Lauric acid conjugate type against L. major: In vitro mechanism of actions and in vivo treatment potentials. PLoS neglected tropical diseases. 2019;13(2):e0007217. DOI: https://doi.org/10.1371/journal.pntd.0007217

Morake M, Coertzen D, Ngwane A, Wentzel JF, Wong HN, Smit FJ, et al. Preliminary evaluation of artemisinin–cholesterol conjugates as potential drugs for the treatment of intractable forms of malaria and tuberculosis. ChemMedChem. 2018;13(1):67-77. DOI: https://doi.org/10.1002/cmdc.201700579

Chernikov IV, Meschaninova MI, Chernolovskaya EL. Preparation, Determination of Activity, and Biodistribution of Cholesterol-Containing Nuclease-Resistant siRNAs In Vivo. RNA Interference and CRISPR Technologies: Springer; 2020. p. 57-77. DOI: https://doi.org/10.1007/978-1-0716-0290-4_3

Hu L, Quach T, Han S, Lim SF, Yadav P, Senyschyn D, et al. Glyceride‐mimetic prodrugs incorporating self‐immolative spacers promote lymphatic transport, avoid first‐pass metabolism, and enhance oral bioavailability. Angewandte Chemie International Edition. 2016; 55:13700-5. DOI: https://doi.org/10.1002/anie.201604207

Markovic M, Dahan A, Keinan S, Kurnikov I, Aponick A, Zimmermann EM, et al. Phospholipid-based prodrugs for colon-targeted drug delivery: experimental study and in-silico simulations. Pharmaceutics. 2019;11(4):186. DOI: https://doi.org/10.3390/pharmaceutics11040186

Ge L, He X, Zhang Y, Zhang Y, Chai F, Jiang L, et al. A dabigatran etexilate phospholipid complex nanoemulsion system for further oral bioavailability by reducing drug-leakage in the gastrointestinal tract. Nanomedicine: Nanotechnology, Biology and Medicine. 2018;14(4):1455-64. DOI: https://doi.org/10.1016/j.nano.2017.08.009

Qin L, Niu Y, Wang Y, Chen X. Combination of phospholipid complex and submicron emulsion techniques for improving oral bioavailability and therapeutic efficacy of water-insoluble drug. Molecular pharmaceutics. 2018;15(3):1238-47. DOI: https://doi.org/10.1021/acs.molpharmaceut.7b01061

Dahan A, Duvdevani R, Shapiro I, Elmann A, Finkelstein E, Hoffman A. The oral absorption of phospholipid prodrugs: In vivo and in vitro mechanistic investigation of trafficking of a lecithin-valproic acid conjugate following oral administration. Journal of controlled release. 2008;126(1):1-9. DOI: https://doi.org/10.1016/j.jconrel.2007.10.025

Semalty A, Semalty M, Singh D, Rawat M. Development and physicochemical evaluation of pharmacosomes of diclofenac. Acta Pharmaceutica. 2009; 59:335-44. DOI: https://doi.org/10.2478/v10007-009-0023-x

Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK. Curcumin–phospholipid complex: preparation, therapeutic evaluation and pharmacokinetic study in rats. International journal of pharmaceutics. 2007; 330:155-63. DOI: https://doi.org/10.1016/j.ijpharm.2006.09.025

Olbrich C, Gessner A, Kayser O, Müller RH. Lipid-drug-conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. Journal of drug targeting. 2002;10(5):387-96. DOI: https://doi.org/10.1080/1061186021000001832

Jena SK, Singh C, Dora CP, Suresh S. Development of tamoxifen-phospholipid complex: novel approach for improving solubility and bioavailability. International journal of pharmaceutics. 2014;473(1-2):1-9. DOI: https://doi.org/10.1016/j.ijpharm.2014.06.056

Dora CP, Kushwah V, Katiyar SS, Kumar P, Pillay V, Suresh S, et al. Improved oral bioavailability and therapeutic efficacy of erlotinib through molecular complexation with phospholipid. International journal of pharmaceutics. 2017;534(1-2):1-13. DOI: https://doi.org/10.1016/j.ijpharm.2017.09.071

Lu Y, Zhang Y, Yang Z, Tang X. Formulation of an intravenous emulsion loaded with a clarithromycin–phospholipid complex and its pharmacokinetics in rats. International journal of pharmaceutics. 2009;366(1-2):160-9. DOI: https://doi.org/10.1016/j.ijpharm.2008.09.008

Chhikara BS, Mandal D, Parang K. Synthesis, anticancer activities, and cellular uptake studies of lipophilic derivatives of doxorubicin succinate. Journal of medicinal chemistry. 2012; 55:1500-10. DOI: https://doi.org/10.1021/jm201653u

Forrest ML, Yáñez JA, Remsberg CM, Ohgami Y, Kwon GS, Davies NM. Paclitaxel prodrugs with sustained release and high solubility in poly (ethylene glycol)-b-poly (ε-caprolactone) micelle nanocarriers: pharmacokinetic disposition, tolerability, and cytotoxicity. Pharmaceutical research. 2008; 25:194-206. DOI: https://doi.org/10.1007/s11095-007-9451-9

Duhem N, Danhier F, Pourcelle V, Schumers J-M, Bertrand O, LeDuff CcS, et al. Self-assembling doxorubicin–tocopherol succinate prodrug as a new drug delivery system: Synthesis, characterization, and in vitro and in vivo anticancer activity. Bioconjugate chemistry. 2013; 25:72-81. DOI: https://doi.org/10.1021/bc400326y

Effenberger K, Breyer S, Schobert R. Modulation of doxorubicin activity in cancer cells by conjugation with fatty acyl and terpenyl hydrazones. European journal of medicinal chemistry. 2010;45:1947-54. DOI: https://doi.org/10.1016/j.ejmech.2010.01.037

Zalipsky S, Saad M, Kiwan R, Ber E, Yu N, Minko T. Antitumor activity of new liposomal prodrug of mitomycin C in multidrug resistant solid tumor: insights of the mechanism of action. Journal of drug targeting. 2007;15:518-30. DOI: https://doi.org/10.1080/10611860701499946

Ashwanikumar N, Kumar NA, Nair SA, Kumar GV. 5-Fluorouracil–lipid conjugate: Potential candidate for drug delivery through encapsulation in hydrophobic polyester-based nanoparticles. Acta biomaterialia. 2014; 10:4685-94. DOI: https://doi.org/10.1016/j.actbio.2014.07.032

Semalty A, Semalty M, Rawat BS, Singh D, Rawat M. Pharmacosomes: the lipid-based new drug delivery system. Expert opinion on drug delivery. 2009;6(6):599-612. DOI: https://doi.org/10.1517/17425240902967607

Kuche K, Bhargavi N, Dora CP, Jain S. Drug-phospholipid complex—a go through strategy for enhanced oral bioavailability. AAPS PharmSciTech. 2019; 20:43. DOI: https://doi.org/10.1208/s12249-018-1252-4

Singh C, Bhatt TD, Gill MS, Suresh S. Novel rifampicin–phospholipid complex for tubercular therapy: synthesis, physicochemical characterization and in-vivo evaluation. International journal of pharmaceutics. 2014; 460:220-7. DOI: https://doi.org/10.1016/j.ijpharm.2013.10.043

Beg S, Raza K, Kumar R, Chadha R, Katare O, Singh B. Improved intestinal lymphatic drug targeting via phospholipid complex-loaded nanolipospheres of rosuvastatin calcium. RSC advances. 2016;6(10):8173-87. DOI: https://doi.org/10.1039/C5RA24278A

Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore D, Darnell J. Molecular cell biology. 6th ed: W. H. Freeman; 2007.

Adhikari P, Pal P, Das AK, Ray S, Bhattacharjee A, Mazumder B. Nano lipid-drug conjugate: An integrated review. International journal of pharmaceutics. 2017; 529:629-41. DOI: https://doi.org/10.1016/j.ijpharm.2017.07.039

Han S, Hu L, Quach T, Simpson JS, Edwards GA, Trevaskis NL, et al. Lymphatic transport and lymphocyte targeting of a triglyceride mimetic prodrug is enhanced in a large animal model: studies in greyhound dogs. Molecular pharmaceutics. 2016; 13:3351-61. DOI: https://doi.org/10.1021/acs.molpharmaceut.6b00195

Semalty A, Semalty M, Singh D, Rawat M. Development and characterization of aspirin-phospholipid complex for improved drug delivery. International Journal of Pharmaceutical Sciences and Nanotechnology. 2010; 3:940-7. DOI: https://doi.org/10.37285/ijpsn.2010.3.2.7

Yatvin MB, Stowell MH. Covalent polar lipid-conjugates with biologically active compounds for use in salves. Google Patents; 2002.

Kurz M, Scriba GK. Drug–phospholipid conjugates as potential prodrugs: synthesis, characterization, and degradation by pancreatic phospholipase A2. Chemistry and physics of lipids. 2000;107(2):143-57. DOI: https://doi.org/10.1016/S0009-3084(00)00167-5

Fisher RS, Ho J. Potential new methods for antiepileptic drug delivery. CNS drugs. 2002;16(9):579-93. DOI: https://doi.org/10.2165/00023210-200216090-00001

You Y-J, Kim Y, Nam N-H, Ahn B-Z. Antitumor activity of unsaturated fatty acid esters of 4′-demethyldeoxypodophyllotoxin. Bioorganic & medicinal chemistry letters. 2003; 13:2629-32. DOI: https://doi.org/10.1016/S0960-894X(03)00558-4

Kawabata K, Takakura Y, Hashida M. The fate of plasmid DNA after intravenous injection in mice: involvement of scavenger receptors in its hepatic uptake. Pharmaceutical research. 1995; 12:825-30. DOI: https://doi.org/10.1023/A:1016248701505

Gupta A, Asthana S, Konwar R, Chourasia M. An insight into potential of nanoparticles-assisted chemotherapy of cancer using gemcitabine and its fatty acid prodrug: a comparative study. Journal of biomedical nanotechnology. 2013; 9:915-25. DOI: https://doi.org/10.1166/jbn.2013.1591

Chue P, Chue J. A review of paliperidone palmitate. Expert review of neurotherapeutics. 2012; 12:1383-97. DOI: https://doi.org/10.1586/ern.12.137